Isabel Ortuño-LizarÃ;n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7700017/publications.pdf

Version: 2024-02-01

| | | 840776 | 996975 | |
|----------|----------------|--------------|----------------|--|
| 15 | 681 | 11 | 15 | |
| papers | citations | h-index | g-index | |
| | | | | |
| | | | | |
| | | | | |
| 15 | 15 | 15 | 1002 | |
| all docs | docs citations | times ranked | citing authors | |
| | | | | |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Phosphorylated αâ€synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Movement Disorders, 2018, 33, 1315-1324. | 3.9 | 113 |
| 2 | Cellular Characterization of OCT and Outer Retinal Bands Using Specific Immunohistochemistry Markers and Clinical Implications. Ophthalmology, 2018, 125, 407-422. | 5.2 | 96 |
| 3 | Retinal α-synuclein deposits in Parkinson's disease patients and animal models. Acta Neuropathologica, 2019, 137, 379-395. | 7.7 | 79 |
| 4 | Interpretation of OCT and OCTA images from a histological approach: Clinical and experimental implications. Progress in Retinal and Eye Research, 2020, 77, 100828. | 15.5 | 77 |
| 5 | Metal–Organic Frameworks as Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics. ACS Applied Materials & Drug Delivery Platforms for Ocular Therapeutics for Ocular | 8.0 | 73 |
| 6 | Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease. Acta Neuropathologica Communications, 2018, 6, 90. | 5.2 | 56 |
| 7 | Dopaminergic Retinal Cell Loss and Visual Dysfunction in Parkinson Disease. Annals of Neurology, 2020, 88, 893-906. | 5.3 | 52 |
| 8 | Correlating synthesis parameters with physicochemical properties of poly(glycerol sebacate). European Polymer Journal, 2017, 87, 406-419. | 5.4 | 44 |
| 9 | Photosensitive Melanopsin-Containing Retinal Ganglion Cells in Health and Disease: Implications for Circadian Rhythms. International Journal of Molecular Sciences, 2019, 20, 3164. | 4.1 | 36 |
| 10 | Influence of synthesis parameters on hyaluronic acid hydrogels intended as nerve conduits. Biofabrication, 2016, 8, 045011. | 7.1 | 19 |
| 11 | Pathologic confirmation of retinal ganglion cell loss in multiple system atrophy. Neurology, 2017, 88, 2233-2235. | 1.1 | 11 |
| 12 | The Absence of Toll-Like Receptor 4 Mildly Affects the Structure and Function in the Adult Mouse Retina. Frontiers in Cellular Neuroscience, 2019, 13, 59. | 3.7 | 10 |
| 13 | Visual Disfunction due to the Selective Effect of Glutamate Agonists on Retinal Cells. International Journal of Molecular Sciences, 2021, 22, 6245. | 4.1 | 9 |
| 14 | Reply. Ophthalmology, 2018, 125, e48-e49. | 5.2 | 4 |
| 15 | Neuroprotective Effects of Tauroursodeoxicholic Acid Involves Vascular and Glial Changes in Retinitis Pigmentosa Model. Frontiers in Neuroanatomy, 2022, 16, 858073. | 1.7 | 2 |